-
Mashup Score: 0Survival Boost With Oncolytic Virus Combo in Glioblastoma Subset - 12 month(s) ago
However, small trial failed to meet overall response endpoint in patients with recurrent disease
Source: www.medpagetoday.comCategories: Latest Headlines, Oncologists2Tweet
-
Mashup Score: 0FLT3 Inhibitor Doubles Overall Survival in Acute Myeloid Leukemia - 12 month(s) ago
Median OS improved from 15 months to nearly 32 months with quizartinib
Source: www.medpagetoday.comCategories: Latest Headlines, Oncologists2Tweet
-
Mashup Score: 0
Device allows delivery of more potent chemotherapies to patients with glioblastomas
Source: www.medpagetoday.comCategories: Latest Headlines, Oncologists2Tweet
-
Mashup Score: 0Antibody-Drug Conjugate Gets FDA Thumbs Up for Untreated DLBCL - 1 year(s) ago
Adding polatuzumab vedotin to a modified version of R-CHOP significantly improved PFS
Source: www.medpagetoday.comCategories: Latest Headlines, Oncologists2Tweet
-
Mashup Score: 0
Chemotherapy regimens with higher cumulative dose provide greatest benefit
Source: www.medpagetoday.comCategories: Latest Headlines, Oncologists2Tweet
-
Mashup Score: 0
Caregivers of those with other conditions also see consequences
Source: www.medpagetoday.comCategories: Latest Headlines, Oncologists2Tweet
-
Mashup Score: 0
Carcinogenic associations between obesity and cancer risk are reversible, study authors suggest
Source: www.medpagetoday.comCategories: Latest Headlines, Oncologists2Tweet
-
Mashup Score: 0Older Men Still Overscreened for Prostate Cancer, Survey Says - 1 year(s) ago
PSA screening rates over 50% for men 70 and up, despite USPSTF recommendations against it
Source: www.medpagetoday.comCategories: Latest Headlines, Oncologists2Tweet
-
Mashup Score: 0SYK Inhibitor Promising in Early Trial of Primary ITP - 1 year(s) ago
Sovleplenib demonstrated ‘consistent response’ as second-line treatment
Source: www.medpagetoday.comCategories: Latest Headlines, Oncologists2Tweet
-
Mashup Score: 0CAR T-Cell Therapy Feasible, Safe in Advanced Neuroblastoma - 1 year(s) ago
ORR of 63% with GD2-targeting product in kids with relapsed, refractory high-risk disease
Source: www.medpagetoday.comCategories: Latest Headlines, Oncologists2Tweet
The combination of oncolytic DNX-2401 virotherapy with #Keytruda failed to meet a phase I/II study's primary endpoint of #ORR in patients with recurrent #glioblastoma, but did demonstrate a "notable survival benefit" in select patients. #OncoTwitter https://t.co/bcCHTQOaCK